This is exemplified in a study by Apostolaki et al. [262], who assessed a cohort of 214 early stage breast cancer patients and found that 8 of 161 prechemotherapy HER2− patients had become HER2+ following treatment, which was associated with a worse DFS. This evidence concerns the gene ERBB2 and breast cancer.